CA
NZ
UK
AU
IND
US
Palisade Bio, Inc. (NASDAQ: PALI), a clinical-stage biopharmaceutical company focused on autoimmune, inflammatory, and fibrotic diseases, has announced the completion of enrollment and dosing across multiple cohorts in its ongoing Phase 1a/b study of PALI-2108 for the treatment of Ulcerative Colitis (UC). This includes …
Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) has announced the completion of participant enrollment in its Phase 2a clinical trial for LP-310, a liposomal tacrolimus oral rinse designed to treat oral lichen planus (OLP), a condition that currently has no FDA-approved treatments. This trial, which includes …
CureVac N.V. (Nasdaq: CVAC), a biotechnology company focused on mRNA-based medicines, announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for a Phase 1 clinical study of CVHNLC. This therapy is an mRNA-based precision immunotherapy designed …
Mesoblast (Nasdaq: MESO) has confirmed that its allogeneic cellular products, including Ryoncil® and Revascor®, will be exempt from U.S. tariffs. This exemption is made possible because the company’s products are designated as “U.S. Country of Origin” products. All products are manufactured using U.S. donors …
Telix Pharmaceuticals (ASX/NASDAQ: TLX) has appointed Anne Whitaker as a Non-Executive Director, effective April 7, 2025. Whitaker's appointment brings a wealth of knowledge and experience to the company, stemming from over three decades in the pharmaceutical, biotech, and specialty pharmaceutical sectors.
Eli Lilly and Company (NYSE:LLY) has announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to lower lipoprotein(a) [Lp(a)] levels, a genetic risk factor for cardiovascular disease. The ALPACA study results confirm that lepodisiran successfully met its primary …
Mesoblast (Nasdaq:MESO; ASX:MSB), a global leader in allogeneic cellular medicines, has announced a major milestone for its FDA-approved mesenchymal stromal cell (MSC) therapy, Ryoncil® (remestemcel-L). The company has entered into a National Drug Rebate Agreement (NDRA) with the U.S. Centers for Medicare & Medicaid …
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted marketing and manufacturing authorization for Dupixent® (dupilumab) to treat chronic obstructive pulmonary disease (COPD) in adults whose condition is not well-managed with existing therapies. This …
Innate Pharma SA (Nasdaq:IPHA)has announced its financial results for the year ending December 31, 2024, alongside notable advancements in its clinical pipeline. The company continues to make progress in immuno-oncology, securing regulatory recognition and funding to support ongoing research efforts.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) has announced significant progress in the development of its proprietary antisense oligonucleotide (ASO) drug candidate, HT-KIT. The biopharmaceutical company is focused on creating therapies for allergic and inflammatory diseases, and HT-KIT represents an innovative approach to treating conditions such …
Please wait processing your request...